0000000000975145

AUTHOR

Mira Ahinko

showing 11 related works from this author

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

2018

Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease. Coumarin with a functionalized 3-phenyl ring system is a promising scaffold for building potent MAO-B inhibitors. Here, a vast set of 3-phenylcoumarin derivatives was designed using virtual combinatorial chemistry or rationally de novo and synthesized using microwave chemistry. The derivatives inhibited the MAO-B at 100 nM−1 μM. The IC50 value of the most potent derivative 1 was 56 nM. A docking-based structure-activi…

0301 basic medicineentsyymitParkinson's diseaseParkinsonin tautita311101 natural scienceslääkesuunnittelumonoamine oxidase B (MAO-B)lcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)Dopamine3-phenylcoumarinmedicineStructure–activity relationshipoksidoreduktaasitkumariinitta116ta317inhibiittoritOriginal Researchchemistry.chemical_classificationbiologyvirtual drug designta1182General ChemistryCoumarin3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryChemistry030104 developmental biologyMonoamine neurotransmitterEnzymeBiochemistrychemistrylcsh:QD1-999Docking (molecular)biology.proteinParkinson’s diseaseMonoamine oxidase BMonoamine oxidase Amedicine.drugFrontiers in Chemistry
researchProduct

Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives

2018

A comprehensive set of 3-phenylcoumarin analogues with polar substituents was synthesised for blocking oestradiol synthesis by 17-b-hydroxysteroid dehydrogenase 1 (HSD1) in the latter part of the sulphatase pathway. Five analogues produced 62% HSD1 inhibition at 5 mM and, furthermore, three of them produced 68% inhibition at 1 mM. A docking-based structure-activity relationship analysis was done to determine the molecular basis of the inhibition and the cross-reactivity of the analogues was tested against oestrogen receptor, aromatase, cytochrome P450 1A2, and monoamine oxidases. Most of the analogues are only modestly active with 17-b-hydroxysteroid dehydrogenase 2 – a requirement for lowe…

0301 basic medicinearomatase17-Hydroxysteroid Dehydrogenasesmedicine.drug_classStereochemistry3-imidazolecoumarinaromataasiDehydrogenaseta3111LigandsStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)0302 clinical medicineCoumarinsIn vivo17-β-hydroxysteroid dehydrogenase 1 (HSD1)Drug DiscoverymedicineHumansMoietyEnzyme InhibitorsAromatasePharmacologyAromatase inhibitorDose-Response Relationship DrugEstradiolMolecular StructurebiologyChemistrylcsh:RM1-950CYP1A2ta1182General MedicineCoumarin3. Good healthMolecular Docking Simulationlcsh:Therapeutics. Pharmacology030104 developmental biologyDocking (molecular)030220 oncology & carcinogenesisbiology.proteinComputer-Aided Design3-Phenylcoumarinhormones hormone substitutes and hormone antagonistsResearch PaperJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct

Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors.

2019

A novel virtual screening methodology called fragment- and negative image-based (F-NiB) screening is introduced and tested experimentally using phosphodiesterase 10A (PDE10A) as a case study. Potent PDE10A-specific small-molecule inhibitors are actively sought after for their antipsychotic and neuroprotective effects. The F-NiB combines features from both fragment-based drug discovery and negative image-based (NIB) screening methodologies to facilitate rational drug discovery. The selected structural parts of protein-bound ligand(s) are seamlessly combined with the negative image of the target's ligand-binding cavity. This cavity- and fragment-based hybrid model, namely its shape and electr…

PharmacologyVirtual screening010405 organic chemistryDrug discoveryChemistryPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesOrganic ChemistryFragment-based lead discoveryAb initioDrug Evaluation PreclinicalPhosphodiesteraseComputational biology01 natural sciencesBiochemistrySmall molecule0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)Drug DiscoveryMolecular MedicineHumansPharmacophoreChemical biologydrug designREFERENCES
researchProduct

Substrate Selectivity of Coumarin Derivatives by Human CYP1 Enzymes: In Vitro Enzyme Kinetics and In Silico Modeling

2021

Of the three enzymes in the human cytochrome P450 family 1, CYP1A2 is an important enzyme mediating metabolism of xenobiotics including drugs in the liver, while CYP1A1 and CYP1B1 are expressed in extrahepatic tissues. Currently used CYP substrates, such as 7-ethoxycoumarin and 7-ethoxyresorufin, are oxidized by all individual CYP1 forms. The main aim of this study was to find profluorescent coumarin substrates that are more selective for the individual CYP1 forms. Eleven 3-phenylcoumarin derivatives were synthetized, their enzyme kinetic parameters were determined, and their interactions in the active sites of CYP1 enzymes were analyzed by docking and molecular dynamic simulations. All cou…

entsyymitStereochemistryGeneral Chemical EngineeringCYP1B1Articlechemistry.chemical_compoundheterocyclic compoundsEnzyme kineticsQD1-999chemistry.chemical_classificationbiologysytokromitChemistryCYP1A2Substrate (chemistry)Active sitelääkeaineetGeneral Chemistryrespiratory systemCoumarinChemistrylääkkeetEnzymeDocking (molecular)biology.proteinbiolääketiedeACS Omega
researchProduct

Suitability ofMMGBSAfor the selection of correct ligand binding modes from docking results

2018

The estimation of the correct binding mode and affinity of a ligand into a target protein using computational methods is challenging. However, docking can introduce poses from which the correct binding mode could be identified using other methods. Here, we analyzed the reliability of binding energy estimation using the molecular mechanics-generalized Born surface area (MMGBSA) method without and with energy minimization to identify the likely ligand binding modes within docking results. MMGBSA workflow (a) outperformed docking in recognizing the correct binding modes of androgen receptor ligands and (b) improved the correlation coefficient of computational and experimental results of rescor…

Molecular modelBinding energyta3111LigandsEnergy minimization01 natural sciencesBiochemistrylääkesuunnitteluSubstrate SpecificityCytochrome P-450 CYP2A6Free energy perturbationCoumarinsDrug DiscoveryHumansta317PharmacologyBinding Sitesmolecular modeling010405 organic chemistryChemistryDrug discoveryOrganic Chemistryta1182liganditreceptor and ligandslaskennallinen kemiaLigand (biochemistry)Protein Structure Tertiary0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)structure based drug-designThermodynamicsMolecular MedicineproteiinitTarget proteinBiological systemProtein BindingChemical Biology & Drug Design
researchProduct

Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes

2018

Cytochrome P450 (CYP) enzymes constitute an essential xenobiotic metabolizing system that regulates the elimination of lipophilic compounds from the body. Convenient and affordable assays for CYP enzymes are important for assessing these metabolic pathways.In this study, 10 novel profluorescent coumarin derivatives with various substitutions at carbons 3, 6 and 7 were developed. Molecular modeling indicated that 3-phenylcoumarin offers an excellent scaffold for the development of selective substrate compounds for various human CYP forms, as they could be metabolized to fluorescent 7-hydroxycoumarin derivatives. Oxidation of profluorescent coumarin derivatives to fluorescent metabolites by 1…

Models MolecularentsyymitoxidationHealth Toxicology and MutagenesisToxicology030226 pharmacology & pharmacyBiochemistrycoumarinFluorescence03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCytochrome P-450 Enzyme SystemCoumarinsCYPenzyme kineticsderivativeCytochrome P-450 Enzyme InhibitorsHumansheterocyclic compoundsEnzyme kineticskumariiniCYP2A6ta317Pharmacologychemistry.chemical_classificationBenzoflavonesbiologyChemistryCYP1A2fluoresenssiCytochrome P450substraatit (kemia)General MedicineCoumarindrug metabolismMolecular Docking SimulationMetabolic pathwayKineticsEnzymeBiochemistrylääkekemia030220 oncology & carcinogenesisInactivation Metabolicbiology.proteinMicrosomes LiverOxidation-ReductionDrug metabolism
researchProduct

Improving Docking Performance Using Negative Image-Based Rescoring

2017

Despite the large computational costs of molecular docking, the default scoring functions are often unable to recognize the active hits from the inactive molecules in large-scale virtual screening experiments. Thus, even though a correct binding pose might be sampled during the docking, the active compound or its biologically relevant pose is not necessarily given high enough score to arouse the attention. Various rescoring and post-processing approaches have emerged for improving the docking performance. Here, it is shown that the very early enrichment (number of actives scored higher than 1% of the highest ranked decoys) can be improved on average 2.5-fold or even 8.7-fold by comparing th…

0301 basic medicineComputer scienceEnergy minimizationconsensus scoring03 medical and health sciencesmolekyylilääketiedeta318Pharmacology (medical)benchmarkingdocking rescoringOriginal ResearchPharmacologyVirtual screeningDrug discoverybusiness.industrylcsh:RM1-950Pattern recognitionmolecular dockingnegative image-based rescoring (R-NiB)030104 developmental biologylcsh:Therapeutics. PharmacologyActive compoundDocking (molecular)Target proteinArtificial intelligencebusinessFrontiers in Pharmacology
researchProduct

A Practical Perspective : The Effect of Ligand Conformers on the Negative Image-Based Screening

2019

Negative image-based (NIB) screening is a rigid molecular docking methodology that can also be employed in docking rescoring. During the NIB screening, a negative image is generated based on the target protein’s ligand-binding cavity by inverting its shape and electrostatics. The resulting NIB model is a drug-like entity or pseudo-ligand that is compared directly against ligand 3D conformers, as is done with a template compound in the ligand-based screening. This cavity-based rigid docking has been demonstrated to work with genuine drug targets in both benchmark testing and drug candidate/lead discovery. Firstly, the study explores in-depth the applicability of different ligand 3D conformer…

entsyymitmolekyylilääketiedestructure-based drug discoveryrigid dockingmolecular dockingliganditdocking rescoringnegative image-based (NIB) screeningvirtual screeningcyclooxygenase-2 (COX-2)negative image-based rescoring (R-NiB)lääkesuunnittelu
researchProduct

Suitability of MMGBSA for the selection of correct ligand binding modes from docking results

2019

The estimation of the correct binding mode and affinity of a ligand into a target protein using computational methods is challenging. However, docking can introduce poses from which the correct binding mode could be identified using other methods. Here, we analyzed the reliability of binding energy estimation using the molecular mechanics‐generalized Born surface area (MMGBSA) method without and with energy minimization to identify the likely ligand binding modes within docking results. MMGBSA workflow (a) outperformed docking in recognizing the correct binding modes of androgen receptor ligands and (b) improved the correlation coefficient of computational and experimental results of rescor…

molecular modelingstructure based drug-designreceptor and ligandsproteiinitliganditlaskennallinen kemiadrug discoverylääkesuunnittelu
researchProduct

Improving Docking Performance Using Negative Image-Based Rescoring

2018

Despite the large computational costs of molecular docking, the default scoring functions are often unable to recognize the active hits from the inactive molecules in large-scale virtual screening experiments. Thus, even though a correct binding pose might be sampled during the docking, the active compound or its biologically relevant pose is not necessarily given high enough score to arouse the attention. Various rescoring and post-processing approaches have emerged for improving the docking performance. Here, it is shown that the very early enrichment (number of actives scored higher than 1% of the highest ranked decoys) can be improved on average 2.5-fold or even 8.7-fold by comparing th…

consensus scoringmolekyylilääketiedemolecular dockingbenchmarkingdocking rescoringnegative image-based rescoring (R-NiB)
researchProduct

Fragment‐ and Negative Image‐Based Screening of Phosphodiesterase 10A Inhibitors

2019

A novel virtual screening methodology called fragment‐ and negative image‐based (F‐NiB) screening is introduced and tested experimentally using phosphodiesterase 10A (PDE10A) as a case study. Potent PDE10A‐specific small‐molecule inhibitors are actively sought after for their antipsychotic and neuroprotective effects. The F‐NiB combines features from both fragment‐based drug discovery and negative image‐based (NIB) screening methodologies to facilitate rational drug discovery. The selected structural parts of protein‐bound ligand(s) are seamlessly combined with the negative image of the target's ligand‐binding cavity. This cavity‐ and fragment‐based hybrid model, namely its shape and electr…

skitsofreniastructure-based virtual screeningseulontaParkinsonin tautivirtual screeningfragmentnegative image based (FNiB) screeningphosphodiesterase 10A (PDE10A)schizophrenianegative image based (NIB)lääkkeetParkinson’s diseaseradiometric activity assayfragment-based drug discoveryHuntingtonin tautiHuntington’s disease
researchProduct